Show simple item record

dc.contributor.authorFlux, GD
dc.date.accessioned2018-02-19T12:43:08Z
dc.date.issued2017-08
dc.identifier.citationThe British journal of radiology, 2017, 90 (1077), pp. 20160748 - ?
dc.identifier.issn0007-1285
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1297
dc.identifier.eissn1748-880X
dc.identifier.doi10.1259/bjr.20160748
dc.description.abstractRadium-223 ( 223 Ra) offers a new option for the treatment of bone metastases from prostate cancer. As cancer treatment progresses towards personalization, the potential for an individualized approach is exemplified in treatments with radiotherapeutics due to the unique ability to image in vivo the uptake and retention of the therapeutic agent. This is unmatched in any other field of medicine. Currently, 223 Ra is administered according to standard fixed administrations, modified according to patient weight. Although gamma emissions comprise only 1% of the total emitted energy, there are increasing reports that quantitative imaging is feasible and can facilitate patient-specific dosimetry. The aim of this article is to review the application of imaging and dosimetry for 223 Ra and to consider the potential for treatment optimization accordingly, in order to ensure clinical and cost effectiveness of this promising agent.
dc.formatPrint-Electronic
dc.format.extent20160748 - ?
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0
dc.subjectHumans
dc.subjectBone Neoplasms
dc.subjectProstatic Neoplasms
dc.subjectRadium
dc.subjectRadioisotopes
dc.subjectRadiometry
dc.subjectMale
dc.subjectPrecision Medicine
dc.titleImaging and dosimetry for radium-223: the potential for personalized treatment.
dc.typeJournal Article
rioxxterms.versionofrecord10.1259/bjr.20160748
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc/4.0
rioxxterms.licenseref.startdate2017-08
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfThe British journal of radiology
pubs.issue1077
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics/Radioisotope Physics (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics/Radioisotope Physics (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume90
pubs.embargo.termsNot known
icr.researchteamRadioisotope Physicsen_US
dc.contributor.icrauthorFlux, Glennen
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/4.0